vs
Community West Bancshares（CWBC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Community West Bancshares的季度营收约是REGENXBIO Inc.的1.3倍（$38.3M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs 11.6%），Community West Bancshares自由现金流更多（$43.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 36.0%）
Community West Bancshares是一家总部位于美国加利福尼亚州的注册银行控股公司，依据银行控股公司相关法案全资持有Community West Bank，开展银行相关控股经营业务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CWBC vs RGNX — 直观对比
营收规模更大
CWBC
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出31.4%
11.6%
自由现金流更多
CWBC
多$96.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
36.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.3M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 40.0% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 11.6% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.58 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CWBCRGNX
| Q4 25 | $38.3M | $30.3M | ||
| Q3 25 | $37.9M | $29.7M | ||
| Q2 25 | $35.7M | $21.4M | ||
| Q1 25 | $34.8M | $89.0M | ||
| Q4 24 | $34.3M | $21.2M | ||
| Q3 24 | $31.3M | $24.2M | ||
| Q2 24 | $30.5M | $22.3M | ||
| Q1 24 | $20.7M | $15.6M |
净利润CWBCRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $10.9M | $-61.9M | ||
| Q2 25 | $7.8M | $-70.9M | ||
| Q1 25 | $8.3M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $3.4M | $-59.6M | ||
| Q2 24 | $-6.3M | $-53.0M | ||
| Q1 24 | $3.7M | $-63.3M |
毛利率CWBCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CWBCRGNX
| Q4 25 | 40.0% | -190.0% | ||
| Q3 25 | 39.8% | -176.3% | ||
| Q2 25 | 30.2% | -296.3% | ||
| Q1 25 | 32.7% | 13.6% | ||
| Q4 24 | 31.0% | -242.1% | ||
| Q3 24 | 13.3% | -256.6% | ||
| Q2 24 | -25.9% | -251.3% | ||
| Q1 24 | 23.2% | -408.8% |
净利率CWBCRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 28.7% | -208.3% | ||
| Q2 25 | 22.0% | -331.8% | ||
| Q1 25 | 23.8% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 10.8% | -246.3% | ||
| Q2 24 | -20.7% | -237.7% | ||
| Q1 24 | 17.8% | -405.4% |
每股收益（稀释后）CWBCRGNX
| Q4 25 | $0.58 | $-1.30 | ||
| Q3 25 | $0.57 | $-1.20 | ||
| Q2 25 | $0.41 | $-1.38 | ||
| Q1 25 | $0.44 | $0.12 | ||
| Q4 24 | $0.29 | $-0.99 | ||
| Q3 24 | $0.18 | $-1.17 | ||
| Q2 24 | $-0.33 | $-1.05 | ||
| Q1 24 | $0.31 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $119.0M | $230.1M |
| 总债务越低越好 | $69.5M | — |
| 股东权益账面价值 | $409.6M | $102.7M |
| 总资产 | $3.7B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资CWBCRGNX
| Q4 25 | $119.0M | $230.1M | ||
| Q3 25 | $121.6M | $274.2M | ||
| Q2 25 | $134.4M | $323.3M | ||
| Q1 25 | $148.4M | $267.9M | ||
| Q4 24 | $120.4M | $234.7M | ||
| Q3 24 | $149.0M | $255.5M | ||
| Q2 24 | $109.7M | $290.4M | ||
| Q1 24 | $61.0M | $338.7M |
总债务CWBCRGNX
| Q4 25 | $69.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $69.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CWBCRGNX
| Q4 25 | $409.6M | $102.7M | ||
| Q3 25 | $397.6M | $161.5M | ||
| Q2 25 | $380.0M | $213.7M | ||
| Q1 25 | $372.2M | $274.2M | ||
| Q4 24 | $362.7M | $259.7M | ||
| Q3 24 | $363.5M | $301.4M | ||
| Q2 24 | $350.2M | $348.3M | ||
| Q1 24 | $211.7M | $390.7M |
总资产CWBCRGNX
| Q4 25 | $3.7B | $453.0M | ||
| Q3 25 | $3.6B | $525.2M | ||
| Q2 25 | $3.6B | $581.0M | ||
| Q1 25 | $3.6B | $490.9M | ||
| Q4 24 | $3.5B | $466.0M | ||
| Q3 24 | $3.5B | $519.1M | ||
| Q2 24 | $3.5B | $569.4M | ||
| Q1 24 | $2.4B | $629.2M |
负债/权益比CWBCRGNX
| Q4 25 | 0.17× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $43.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 113.9% | -174.0% |
| 资本支出强度资本支出/营收 | 6.6% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $77.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CWBCRGNX
| Q4 25 | $46.1M | $-52.3M | ||
| Q3 25 | $13.2M | $-56.0M | ||
| Q2 25 | $11.5M | $-49.3M | ||
| Q1 25 | $11.1M | $33.6M | ||
| Q4 24 | $22.2M | $-31.6M | ||
| Q3 24 | $7.8M | $-40.5M | ||
| Q2 24 | $5.2M | $-45.5M | ||
| Q1 24 | $4.0M | $-55.5M |
自由现金流CWBCRGNX
| Q4 25 | $43.6M | $-52.8M | ||
| Q3 25 | $12.8M | $-56.5M | ||
| Q2 25 | $10.6M | $-49.7M | ||
| Q1 25 | $10.8M | $32.6M | ||
| Q4 24 | $17.2M | $-32.7M | ||
| Q3 24 | $5.2M | $-40.9M | ||
| Q2 24 | $4.8M | $-46.0M | ||
| Q1 24 | $3.6M | $-56.0M |
自由现金流率CWBCRGNX
| Q4 25 | 113.9% | -174.0% | ||
| Q3 25 | 33.7% | -189.9% | ||
| Q2 25 | 29.6% | -232.8% | ||
| Q1 25 | 30.9% | 36.6% | ||
| Q4 24 | 50.0% | -154.2% | ||
| Q3 24 | 16.7% | -168.9% | ||
| Q2 24 | 15.7% | -206.2% | ||
| Q1 24 | 17.3% | -358.5% |
资本支出强度CWBCRGNX
| Q4 25 | 6.6% | 1.7% | ||
| Q3 25 | 1.1% | 1.7% | ||
| Q2 25 | 2.7% | 1.8% | ||
| Q1 25 | 0.9% | 1.2% | ||
| Q4 24 | 14.7% | 5.1% | ||
| Q3 24 | 8.1% | 1.3% | ||
| Q2 24 | 1.4% | 2.1% | ||
| Q1 24 | 2.1% | 3.6% |
现金转化率CWBCRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.21× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.33× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.29× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.09× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CWBC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
